✦ LIBER ✦

Stability of 111In-bleomycin in normal and tumor-bearing mice

✍ Scribed by De-Yan Hou; Hans Hoch; Gerald S. Johnston; K.C. Tsou; Raymond J. Farkas; Elizabeth E. Miller

Publisher: Elsevier Science
Year: 1982
Tongue: English
Weight: 197 KB
Volume: 8
Category: Article
ISSN: 0360-3016
DOI: 10.1016/0360-3016(82)90368-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A new 111in-bleomycin complex for tumor

A new 111in-bleomycin complex for tumor imaging: Preparation, stability, and distribution in glioma-bearing mice

✍ De-Yan Hou; Hans Hoch; Gerald S. Johnston; K. C. Tsou; Alfred E. Jones; Raymond 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 895 KB

## Abstract A new ^111^In‐bleomycin complex (^111^In‐BLMC) is here reported. Its radiochemical purity was 99% by thin‐layer chromatography (TLC) (Rf 0.65) and in 5% agarose gel electrophoresis in 0.02 M NaHCO~3~ it migrated toward the anode. Autoradiographs of TLC and gel electrophoresis plates sho

Comparison of oncophilic radiopharmaceut

Comparison of oncophilic radiopharmaceuticals, *I-fibrinogen, 67Ga- citrate, 111In-bleomycin, and *I-bleomycin in tumor-bearing mice

✍ Gerald L. Denardo; Kenneth A. Krohn; Sally J. Denardo 📂 Article 📅 1977 🏛 John Wiley and Sons 🌐 English ⚖ 556 KB

The pharmacokinetics of E7Ga-citrate, "'In-bleomycin, \*I-bleomycin, and \*Ifibrinogen were compared in a murine KHJJ tumor model in order to assess their relative potential as agents for in vivo detection of cancer. Although all four agents have been reported to be clinically efficacious, in this t

Plasminogen activator in normal and tumo

Plasminogen activator in normal and tumor-bearing mice

✍ Margaret R. Bruesch; Gail L. Johnson; Carol S. Palackdharry; Michael J. Weber; P 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 French ⚖ 699 KB

## Abstract The plasminogen activator levels of a series of murine tumors commonly used in cancer drug screening were determined and compared to the levels found in normal mouse tissues. Tumors high in plasminogen activator included the B16 and colon 26. The Lewis lung and M5076 carcinoma showed an

A new tumor imaging agent-111In-bleomyci

A new tumor imaging agent-111In-bleomycin complex. Comparison with 67Ga-citrate and 57Co-Bleomycin in tumor-bearing animals

✍ De-Yan Hou; Hans Hoch; Gerald S. Johnston; K. C. Tsou; Alfred E. Jones; Elizabet 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 778 KB

## Abstract We have found a new ^111^In‐bleomycin complex (BLMC), which has high affinity to tumor, does not bind to transferrin and is stable in vivo. Distribution in animals bearing glioma, hepatoma, or mammary adenocarcinoma at 48 hours showed: the ratios of tumor to blood, brain, heart, lung, l

Use of 111in-bleomycin for combining rad

Use of 111in-bleomycin for combining radiotherapy and chemotherapy on glioma-bearing mice

✍ De-Yan Hou; Hans Hoch; Gerald S. Johnston; K. C. Tsou; Raymond J. Farkas; Elizab 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 624 KB

Mice bearing transplanted glioma received 0.9% NaCl, 0.1 mg of BLM, or 200-250 pCi of "'In-BLM (0.1 mg BLM) daily for 5 days intraperitoneally. After therapy, tumor sizes were in the order NaCl > BLM > "'In-BLM. On the 11th day after the first injection, tumor size (m3) in the "'In-BLM group was 1,2

Mammary tumor virus (MTV) antigens in no

Mammary tumor virus (MTV) antigens in normal and mammary tumor-bearing mice

✍ J. H. M. Hilgers; G. J. Theuns; Robertha Van Nie 📂 Article 📅 1973 🏛 John Wiley and Sons 🌐 French ⚖ 591 KB

## Abstract Quantitative immunofluorescence tests were used to study MTV‐antigen production in normal and mammary tumor‐bearing mice of two low (BALB/c and C3Hf) and two high (C3H and GR) mammary cancer strains. Mammary tumors could be distinguished on the basis of MTV‐antigen expression in two gro